Figures computed from official regulatory filings — .
Analysttarget 17 USD (+1228%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 5.73% · institutions 5.68% · short 3.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Imunon, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
169 buys15 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Tardugno Michael Htrack record | Award | $10.1K | SEC |
| Lindborg Stacy | Award | $9.4K | SEC |
| Faller Douglas Vincent | Award | $6.2K | SEC |
| Tardugno Michael Htrack record | Award | $8.6K | SEC |
| Faller Douglas Vincent | Award | $6.2K | SEC |
| Lindborg Stacy | Award | $8.1K | SEC |
| Lindborg Stacy | Award | $10.9K | SEC |
| Eylward Susan | Award | $4K | SEC |
| Eylward Susan | Sell | $3.9K | SEC |
| Faller Douglas Vincent | Award | $5.8K | SEC |
| Tardugno Michael Htrack record | Award | $11.8K | SEC |
| Eylward Susan | Sell | $4K | SEC |
| Faller Douglas Vincent | Award | $5.8K | SEC |
| Tardugno Michael Htrack record | Award | $11.8K | SEC |
| Eylward Susan | Award | $4K | SEC |
| Lindborg Stacy | Award | $10.9K | SEC |
| Eylward Susan | Award | $4K | SEC |
| Lindborg Stacy | Award | $8K | SEC |
| Braun Donald P | Award | $9.8K | SEC |
| Tardugno Michael Htrack record | Award | $10.1K | SEC |
| PELLIZZARI CHRISTINE Atrack record | Award | $11K | SEC |
| Dentzer James E | Award | $11K | SEC |
| Eylward Susan | Sell | $4K | SEC |
| Faller Douglas Vincent | Award | $5.8K | SEC |
| Fritz Frederick J.track record | Award | $11K | SEC |